M. Augustin1, J. Węgłowska2, M. Lebwohl3, V. Piguet4, H. Sofen5, A. Blauvelt6, L. Peterson7, C. Arendt8, R. Rolleri7
Introduction: The Fc-free, PEGylated, anti-tumour necrosis factor (TNF) certolizumab pegol (CZP), has shown efficacy in adults with plaque psoriasis (PSO) over 48 weeks’ (wks’) treatment.1,2
Objectives: To assess the efficacy of CZP in patients who failed to respond (